Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1415-1422

  Krishna, Gopal ^a   Sansone Parsons, Angela ^a   Kantesaria, Bhavna ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug interaction; Pharmacokinetics; Phenytoin; Posaconazole; Safety

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; PHENYTOIN; POSACONAZOLE; VORICONAZOLE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG HALF LIFE; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MYCOSIS; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBIOTICS, ANTIFUNGAL; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; POLYPHARMACY; TIME FACTORS; TRIAZOLES;

EID: 34347211017     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X187937     Document Type: Article

References (39)

1. Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis 1994;19(Suppl 1):S49-53
2. Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Huntingt) 2001;15:351-63
3. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002;17:113-20
4. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-88
5. Marty F, Mylonakis E. Antifungal use in HIV infection. Expert Opin Pharmacother 2002;3:91-102
6. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
7. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic Importance. Diagn Microbiol Infect Dis 1998;30:121-9
8. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-4
9. Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001;48:769-73
10. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-7
11. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15
12. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2
13. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-8
14. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34
15. Ullmann AJ, Comely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66
16. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5
17. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95
18. Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3-7, 2006 Anaheim, Calif 2006
19. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22
20. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-3
21. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61(Suppl 1):27-37
22. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409-29
23. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51
24. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53
25. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Exp Opin Pharmacother 2005;6:2231-43
26. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80
27. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83-97
28. Mitchell AS, Holland JT. Fluconazole and phenytoin: a predictable interaction [letter]. BMJ 1989;298:1315
29. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5
30. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-24
31. Purkins L, Wood N, Ghahramani P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56 Suppl 1:37-44
32. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982
33. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71
34. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63 (Suppl 4):S3-8
35. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74
36. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63
37. Crowley JJ, Cusack BJ, Jue SG, et al. Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and Cortisol in healthy men. J Pharmacol Exp Ther 1988;245:513-23
38. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 1995;84:292-4
39. Tomlinson B, Young RP, Ng MC, et al. Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Eur J Clin Pharmacol 1996;50:411-15